Provided by Tiger Trade Technology Pte. Ltd.

Celldex Therapeutics

40.57
+0.19000.47%
Post-market: 40.570.00000.00%19:30 EDT
Volume:416.89K
Turnover:16.90M
Market Cap:3.18B
PE:-9.35
High:40.98
Open:40.16
Low:39.53
Close:40.38
52wk High:45.14
52wk Low:21.34
Shares:78.49M
Float Shares:73.02M
Volume Ratio:0.43
T/O Rate:0.57%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.3401
EPS(LYR):-3.9000
ROE:-43.88%
ROA:-27.62%
PB:4.46
PE(LYR):-10.40

Loading ...

Celldex Presents Positive Data from Phase 2 Chronic Spontaneous Urticaria and Phase 2 Cold Urticaria and Symptomatic Dermographism Studies Demonstrating Rapid, Profound and Durable Improvements in Patient Quality of Life at AAD 2026

GlobeNewswire
·
Mar 27

CytoDyn to launch pilot glioblastoma study of leronlimab with temozolomide or radiation

Reuters
·
Mar 24

Celldex Therapeutics Shares Rise After Wolfe Research Upgrade

MT Newswires Live
·
Mar 24

Top Midday Gainers

MT Newswires Live
·
Mar 24

Wolfe Research Upgrades Celldex Therapeutics to Outperform From Peer Perform, PT is $44

MT Newswires Live
·
Mar 23

Celldex upgraded to Outperform from Peer Perform at Wolfe Research

TIPRANKS
·
Mar 23

Celldex Therapeutics Is Maintained at Neutral by Goldman Sachs

Dow Jones
·
Mar 03

Cantor Fitzgerald Reaffirms Their Buy Rating on Celldex (CLDX)

TIPRANKS
·
Mar 02

Celldex presents new data from Phase 2 ColdU, SD Open Label Extension

TIPRANKS
·
Mar 02

Celldex reports Phase 2 data showing barzolvolimab retreatment restores strong efficacy in cold urticaria and symptomatic dermographism

Reuters
·
Mar 01

Guggenheim Sticks to Their Buy Rating for Celldex (CLDX)

TIPRANKS
·
Mar 01

Celldex reports positive Phase 2 barzolvolimab data in chronic urticaria at AAAAI 2026

Reuters
·
Feb 28

Celldex Therapeutics Price Target Raised to $68.00/Share From $58.00 by Stifel

Dow Jones
·
Feb 26

Celldex Therapeutics Inc : Stifel Raises Target Price to $68 From $58

THOMSON REUTERS
·
Feb 26

Morgan Stanley Lifts Price Target on Celldex Therapeutics to $44 From $43, Keeps Overweight Rating

MT Newswires Live
·
Feb 26

Celldex Therapeutics: Early EMBARQ Enrollment and 2026 Data Catalysts Underscore Attractive Risk‑Reward and Support Buy Rating

TIPRANKS
·
Feb 26

Celldex Therapeutics Inc : Morgan Stanley Raises Target Price to $44.00 From $43.00

THOMSON REUTERS
·
Feb 26

Barclays Reaffirms Their Sell Rating on Celldex (CLDX)

TIPRANKS
·
Feb 26

Celldex Q4 net loss hits USD 81.3 million as Q4 revenue totals USD 0.1 million (-89.7%)

Reuters
·
Feb 26

Celldex Therapeutics Q4 EPS USD -1.22 VS. Ibes Estimate USD -1.01

THOMSON REUTERS
·
Feb 26